Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Shares Outstanding (2021 - 2025)

Amylyx Pharmaceuticals has reported Shares Outstanding over the past 5 years, most recently at $109.9 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $109.9 million for Q4 2025, up 60.11% from a year ago — trailing twelve months through Dec 2025 was $109.9 million (up 60.11% YoY), and the annual figure for FY2025 was $109.9 million, up 60.11%.
  • Shares Outstanding for Q4 2025 was $109.9 million at Amylyx Pharmaceuticals, roughly flat from $109.8 million in the prior quarter.
  • Over the last five years, Shares Outstanding for AMLX hit a ceiling of $109.9 million in Q4 2025 and a floor of $6.4 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $67.4 million (2023), compared with a mean of $60.4 million.
  • Biggest five-year swings in Shares Outstanding: soared 847.4% in 2022 and later grew 1.08% in 2024.
  • Amylyx Pharmaceuticals' Shares Outstanding stood at $7.0 million in 2021, then soared by 847.4% to $66.5 million in 2022, then rose by 1.8% to $67.7 million in 2023, then increased by 1.36% to $68.6 million in 2024, then skyrocketed by 60.11% to $109.9 million in 2025.
  • The last three reported values for Shares Outstanding were $109.9 million (Q4 2025), $109.8 million (Q3 2025), and $89.2 million (Q2 2025) per Business Quant data.